6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Development of spiro-3-indolin-2-one containing compounds of antiproliferative and anti-SARS-CoV-2 properties

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A series of 1″-(alkylsulfonyl)-dispiro[indoline-3,2′-pyrrolidine-3′,3″-piperidine]-2,4″-diones 6a‒o has been synthesized through regioselective multi-component azomethine dipolar cycloaddition reaction of 1-(alkylsulfonyl)-3,5-bis(ylidene)-piperidin-4-ones 3ah. X-ray diffraction studies ( 6b‒d, h) confirmed the structures. The majority of the synthesized analogs reveal promising antiproliferation properties against a variety of human cancer cell lines (MCF7, HCT116, A431 and PaCa2) with good selectivity index towards normal cell (RPE1). Some of the synthesized agents exhibit potent inhibitory properties against the tested cell lines with higher efficacies than the standard references (sunitinib and 5-fluorouracil). Compound 6m is the most potent. Multi-targeted inhibitory properties against EGFR and VEGFR-2 have been observed for the synthesized agents. Flow cytometry supports the antiproliferation properties and shows the tested agents as apoptosis and necrosis forming. Vero cell viral infection model demonstrates the anti-SARS-CoV-2 properties of the synthesized agents. Compound 6f is the most promising (about 3.3 and 4.8 times the potency of the standard references, chloroquine and hydroxychloroquine). QSAR models explain and support the observed biological properties.

          Related collections

          Most cited references84

          • Record: found
          • Abstract: not found
          • Article: not found

          Construction of Spiro[pyrrolidine-3,3′-oxindoles] − Recent Applications to the Synthesis of Oxindole Alkaloids

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

            Highlights • On day 14 after the admission, no viral load was detected in arbidol group. • 44.1% of patients in lopinavir/ritonavir group had positive RNA test on day 14. • Patients in the arbidol group had a shorter duration of positive RNA test. • No apparent side effects were found in both groups. • Arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study

              Highlights • Patients were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5–21 days. • Our study shows that oral arbidol and LPV/r in the combination group is associated with a significant elevated negative conversion rate of coronavirus’ test in 7-day and 14-day, compared with LPV/r only in the monotherapy group. • Combination therapy is associated with a significantly improved the chest CT scans in 7-day. • We suppose that reducing the viral load as soon as possible could benefit the delay of the progression of lung lesions.
                Bookmark

                Author and article information

                Contributors
                girgisas10@yahoo.com , as.girgis@nrc.sci.eg
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                16 August 2022
                16 August 2022
                2022
                : 12
                : 13880
                Affiliations
                [1 ]GRID grid.419725.c, ISNI 0000 0001 2151 8157, Department of Pesticide Chemistry, , National Research Centre, ; Dokki, Giza, 12622 Egypt
                [2 ]GRID grid.410427.4, ISNI 0000 0001 2284 9329, Department of Chemistry and Physics, , Augusta University, ; Augusta, GA 30912 USA
                [3 ]GRID grid.419725.c, ISNI 0000 0001 2151 8157, Center of Scientific Excellence for Influenza Viruses, , National Research Centre, ; Giza, 12622 Egypt
                [4 ]GRID grid.5600.3, ISNI 0000 0001 0807 5670, School of Chemistry, , Cardiff University, ; Main Building, Park Place, Cardiff, CF10 3AT UK
                [5 ]GRID grid.419725.c, ISNI 0000 0001 2151 8157, Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, , National Research Centre, ; Dokki, Giza, 12622 Egypt
                [6 ]GRID grid.7776.1, ISNI 0000 0004 0639 9286, Department of Pharmacognosy, Faculty of Pharmacy, , Cairo University, ; Cairo, 11562 Egypt
                [7 ]GRID grid.419725.c, ISNI 0000 0001 2151 8157, Department of Therapeutic Chemistry, , National Research Centre, ; Dokki, Giza, 12622 Egypt
                Article
                17883
                10.1038/s41598-022-17883-9
                9380671
                35974029
                894ab309-f66c-4cf9-87de-5784b5f2fbdc
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 16 May 2022
                : 2 August 2022
                Funding
                Funded by: National Research Centre Egypt
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Uncategorized
                chemical biology,cancer
                Uncategorized
                chemical biology, cancer

                Comments

                Comment on this article